Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oculis Holding ( (OCS) ) has shared an announcement.
On March 3, 2026, Oculis reported its fourth-quarter and full-year 2025 results, highlighting a transformative year marked by clinical advances and a strengthened balance sheet. Cash, cash equivalents and short-term investments rose to $268.7 million as of December 31, 2025, following $210 million of equity financings, extending the company’s cash runway into 2029 despite a wider annual net loss of $119.1 million driven by expanded late-stage development.
Operationally, Oculis advanced three key programs: Privosegtor secured FDA Breakthrough Therapy designation in optic neuritis and initiated the first PIONEER registrational trial in Q4 2025; OCS-01 completed enrollment of more than 800 patients in two Phase 3 DIAMOND trials in diabetic macular edema with topline data expected in Q2 2026; and Licaminlimab entered the PREDICT-1 genotype-based registrational trial in dry eye disease with data expected in Q4 2026. These developments position Oculis for multiple near-term registrational milestones and reinforce its strategy to redefine standards of care across ophthalmology and neuro-ophthalmology, targeting a combined addressable market estimated at over $30 billion.
The most recent analyst rating on (OCS) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.
Spark’s Take on OCS Stock
According to Spark, TipRanks’ AI Analyst, OCS is a Neutral.
The score is held back primarily by weak financial performance (large losses and cash burn despite early revenue growth), partially offset by a strong balance sheet with low leverage. Technicals are supportive due to an established uptrend, but overbought indicators temper the outlook. Valuation is also constrained by negative earnings and no stated dividend yield.
To see Spark’s full report on OCS stock, click here.
More about Oculis Holding
Oculis Holding AG is a global biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, developing late-stage drug candidates to address significant unmet medical needs. Its lead programs target diabetic macular edema with topical eye drops, neuroprotective treatments for optic neuropathies, and precision-medicine therapies for dry eye disease, addressing multi-billion-dollar market opportunities.
Average Trading Volume: 246,709
Technical Sentiment Signal: Buy
Current Market Cap: $1.64B
For an in-depth examination of OCS stock, go to TipRanks’ Overview page.